-
A Phase 2 Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
This is a phase 2 study to test whether the new study medicine, INCB123667 (CDK2 inhibitor), is safe and effective in patients with platinum-resistant ovarian ...
Phase
Interventional